Constantinescu Radu, Romer Megan, McDermott Michael P, Kamp Cornelia, Kieburtz Karl
Department of Neurology, University of Rochester Medical Center, Rochester, New York, USA.
Mov Disord. 2007 Jul 15;22(9):1317-9. doi: 10.1002/mds.21292.
Dyskinesias are a major complication of dopaminergic therapy in the long-term treatment of Parkinson's disease. In the CALM-PD trial, subjects were initially randomized to levodopa or pramipexole and could later add levodopa if needed. After adjusting for disease duration and daily levodopa dosage, the incidence of dyskinesias after initiating levodopa was not significantly different among subjects initially randomized to levodopa and those initially randomized to pramipexole.
运动障碍是帕金森病长期多巴胺能治疗的主要并发症。在CALM-PD试验中，受试者最初被随机分为左旋多巴组或普拉克索组，如有需要，后期可加用左旋多巴。在对病程和每日左旋多巴剂量进行校正后，最初随机分为左旋多巴组和最初随机分为普拉克索组的受试者在开始使用左旋多巴后运动障碍的发生率无显著差异。
